These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 14720633)

  • 1. Incentives and pharmaceutical reimbursement reforms in Spain.
    Puig-Junoy J
    Health Policy; 2004 Feb; 67(2):149-65. PubMed ID: 14720633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical expenditure in Spain: cost and control.
    Lopez Bastida J; Mossialos E
    Int J Health Serv; 2000; 30(3):597-616. PubMed ID: 11109184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany.
    Schwermann T; Greiner W; v d Schulenburg JM
    Value Health; 2003; 6 Suppl 1():S20-30. PubMed ID: 12846923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reference pricing for drugs: is it compatible with U.S. health care?
    Kanavos P; Reinhardt U
    Health Aff (Millwood); 2003; 22(3):16-30. PubMed ID: 12757268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
    Murry L; Gerleman B; Urick B; Urmie J
    J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges to achieving value in drug spending in a decentralized country: the Spanish case.
    Antoñanzas F
    Value Health; 2003; 6 Suppl 1():S52-63. PubMed ID: 12846926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
    Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
    Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
    Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
    Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic aspects of the new Spanish laws on pharmaceutical preparations.
    Antoñanzas F; Oliva J; Pinillos M; Juàrez C
    Eur J Health Econ; 2007 Sep; 8(3):297-300. PubMed ID: 17401592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical reform in South Korea and the lessons it provides.
    Kim HJ; Ruger JP
    Health Aff (Millwood); 2008; 27(4):w260-9. PubMed ID: 18508813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pricing and reimbursement of pharmaceuticals in Sweden.
    Jönsson B
    Pharmacoeconomics; 1994; 6 Suppl 1():51-60. PubMed ID: 10172482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.
    Casanova-Juanes J; Mestre-Ferrandiz J; Espín-Balbino J
    Health Policy; 2018 Dec; 122(12):1310-1315. PubMed ID: 30389186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Rx for reform: a Medicare prescription drug benefit.
    Rak J
    Health Matrix Clevel; 2002; 12(2):449-505. PubMed ID: 12430363
    [No Abstract]   [Full Text] [Related]  

  • 16. Medicaid prescription drug coverage: state efforts to control costs.
    Gencarelli DM
    NHPF Issue Brief; 2003 May; (790):1-17. PubMed ID: 12751504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public drug expenditure in the Republic of Ireland.
    Barry M; Usher C; Tilson L
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating a reasonable reimbursement for community pharmacies in third-party programs.
    Carroll NV
    Manag Care Interface; 1999 Feb; 12(2):73-6, 79-80. PubMed ID: 10346189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Partial reimbursement of prescription charges for generic drugs reduces costs for both health insurance and patients].
    Gouya G; Reichardt B; Bidner A; Weissenfels R; Wolzt M
    Wien Klin Wochenschr; 2008; 120(3-4):89-95. PubMed ID: 18322770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New prescription for the Spanish drug sector: fighting against public deficit without wasting ammunition.
    Antoñanzas F; Gómez P
    Pharmacoeconomics; 2010; 28(11):977-80. PubMed ID: 20936881
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.